Full-Time

Senior Computational Geneticist

Multiple Teams

Posted on 8/12/2026

Deadline 8/19/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$106k - $176.6k/yr

+ 15% bonus target + Share-based long-term incentive program

No H1B Sponsorship

Cambridge, MA, USA

Hybrid

Hybrid role requiring on-site work an average of 2.5 days per week; relocation support may be available.

PhD

Category
Biology & Biotech (1)
Required Skills
LLM
Python
R
SQL
Machine Learning
Perl
Data Analysis

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A PhD and post-doctoral experience in genetics, statistical genetics, or genetic epidemiology with two years of relevant experience are required.
  • Strong statistical and quantitative skills, including knowledge of epidemiological principles and population-based research, are required.
  • Experience managing large projects, collaborations, or consortia is required.
  • Demonstrated experience using generative artificial intelligence tools such as Microsoft Copilot, ChatGPT, Claude, or Gemini to support scientific research, knowledge synthesis, data interpretation, or analytical workflows is required.
  • Understanding of the capabilities, limitations, sources of bias, and appropriate application of large language models and other artificial intelligence technologies in biomedical research is required.
  • Ability to incorporate artificial intelligence-assisted approaches into scientific workflows while maintaining sound scientific judgment and critically evaluating results is required.
  • Experience analyzing genetic datasets and integrating additional data types to advance clinical and biological understanding is required.
  • Proficiency in programming, scripting, querying, or statistical analysis languages such as R, Python, Perl, or SQL is required.
  • Familiarity with genetics platforms is required.
  • Ability to interact and communicate effectively with multidisciplinary scientists, researchers, and non-scientists internally and externally is required.
  • Ability to perform complex statistical analysis is required.
Responsibilities
  • Provide quantitative genetics expertise and conduct analyses through interactions with biologists within the Internal Medicine Research Unit.
  • Apply genetics and functional genomics to identify novel therapeutic targets, review and validate therapeutic hypotheses, understand disease pathogenesis and causal pathways, identify mechanism-related biomarkers by integrating genetics with clinical and omics datasets, identify potential disease indications, and match novel therapies to patients with relevant disease subtypes.
  • Ensure high-quality genetic and omics data are incorporated into exploratory research by interacting with internal partners in statistics, bioinformatics, computational biology, clinical science, and project leadership.
  • Partner with artificial intelligence and machine learning scientists to identify opportunities where artificial intelligence-enabled approaches can enhance genetics-driven target discovery, causal inference, biological interpretation, biomarker identification, and patient stratification.
  • Collaborate with research biologists and project teams to translate genetic and related data into portfolio asset prioritization, and collaborate with clinical teams on patient selection, stratification, and trial design.
  • Evaluate and incorporate artificial intelligence-assisted approaches into genetics research workflows, including literature synthesis, knowledge discovery, biological interpretation, hypothesis generation, and integration of large-scale human genetics and multi-omics datasets.
  • Manage, develop, and maintain internal and external collaborative projects according to specified timelines and milestones.
  • Communicate study findings and analyses to internal partners, leadership, administration, and collaborators.
  • Manage, support, and promote relationships with the external community to add value to target selection and validation.
Desired Qualifications
  • Background in human biology or medicine, with knowledge of disease pathophysiology for metabolic disease.
  • Track record of innovative and impactful research in the genetics of complex traits, including peer-reviewed publications.
  • Experience applying large language models and artificial intelligence-enabled tools to scientific discovery, biological interpretation, literature review, knowledge extraction, or hypothesis generation.
  • Ability to identify opportunities where artificial intelligence can enhance scientific productivity and decision-making while recognizing when human expertise, experimental validation, or additional evidence is required.
  • Scientific leadership experience with responsibility for research project delivery.
  • Experience with at least one additional omics technology, such as metabolomics, lipidomics, transcriptomics, or epigenetics.
  • Ability to identify, propose, and develop new analytical concepts.
  • Ability to lead and support teams, multitask, prioritize competing time-sensitive projects, and work effectively in a multidisciplinary matrix research team.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose to $15 billion, and non-COVID products grew 5% operationally.
  • Pfizer raised 2026 guidance to $60.5 billion-$62.5 billion after Eliquis, Padcev, Vyndaqel strength.
  • Berobenatide entered Phase 3 planning, giving Pfizer a credible obesity franchise before 2028.

What critics are saying

  • Depo-Provera MDL exceeded 5,800 cases by July 2026, with late-2026 bellwethers looming.
  • Vyndamax still faces Apotex litigation in Delaware, preserving generic-entry uncertainty beyond 2031.
  • Ringaskiddy and Catania cuts show manufacturing contraction, signaling more restructuring through 2029.

What makes Pfizer unique

  • Seagen gives Pfizer leading ADCs: Padcev, Tivdak, Adcetris, Tucysa across oncology.
  • Pfizer still owns COMIRNATY distribution scale, with XFG vaccine approved August 27, 2026.
  • Vyndamax settlement extends U.S. exclusivity to June 1, 2031, stabilizing cardiomyopathy cash flows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
Yahoo Finance
Sep 10th, 2026
Medicus Pharma secures Pfizer ADC deal with $2M funding, advances SkinJect for rare cancer treatment

Medicus Pharma has secured a development and licensing agreement with Pfizer for a CD228-targeted antibody-drug conjugate programme focused on solid tumours, including refractory melanoma. Pfizer is providing approximately $2 million in development funding, plus inventory and infrastructure support. CEO Dr Raza Bokhari said the deal allows Medicus to continue from where Pfizer concluded its Phase 1 dose-escalation work, strengthening the company's position in precision oncology. Medicus is also advancing its SkinJect programme for basal cell carcinoma. Final clinical trial results identified the 200-microgram patch as the optimal dose for future studies. The company is preparing for the FDA-approved pivotal SkinJect 005 study whilst recruiting patients. An independent reimbursement analysis suggests SkinJect could achieve reimbursement levels of $25,000 or more per patient.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

Yahoo Finance
Aug 28th, 2026
Pfizer's updated COVID vaccine ships as FDA approves narrower rollout for over-65s and high-risk groups

Pfizer received FDA approval for its updated Comirnaty COVID-19 vaccine on Thursday, with deliveries to pharmacies and clinics beginning immediately. The company's shares were trading at $27.9079 on 28 August. However, the market opportunity has significantly narrowed from pandemic levels. Eligibility is now limited to adults aged 65 and older, plus higher-risk patients aged 5 through 64. Despite Comirnaty having distributed over five billion doses worldwide historically, today's revenue potential is considerably more constrained. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine for this smaller patient pool. The company's current share price sits 5.27% above its estimated value of $26.51, suggesting investors are paying a premium before actual uptake and commercial results become clear.

Associated Press
Aug 27th, 2026
FDA approves Pfizer-BioNTech XFG-adapted COVID-19 vaccine for high-risk groups

Pfizer and BioNTech have received US Food and Drug Administration (FDA) approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant. The vaccine is approved for adults aged 65 and older, and individuals aged 5 to 64 with underlying conditions that increase risk of severe COVID-19 outcomes. The FDA approval is based on clinical, non-clinical and real-world data demonstrating the vaccine generates strong immune responses against currently circulating SARS-CoV-2 variants, including XFG and other contemporary lineages. The XFG variant was selected following FDA guidance for fall 2026 vaccine composition. The vaccine will begin shipping immediately and will be available in US pharmacies, hospitals and clinics within days. To date, more than five billion doses of COMIRNATY have been distributed globally.

Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.

INACTIVE